David Armstrong

Prof. David Armstrong

Limb Preservation Program, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, USA
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Foot and Ankle Research
Verified
Journal Article
Open access
PDF file
David ArmstrongDavid Armstrong
David Armstrong
MSMark A. Swerdlow
Mark A. Swerdlow
AAAlexandria A. Armstrong
Alexandria A. Armstrong
MCMichael S. Conte
Michael S. Conte
WPWilliam V. Padula
William V. Padula
SBSicco A. Bus
Sicco A. Bus
Background: In 2007, we reported a summary of data comparing diabetic foot complications to cancer. The purpose of this brief report was to refresh this with the best available data as they currently exist. Since that time, more reports have emerged both on cancer mortality and mortality associated with diabetic foot ulcer (DFU), Charcot arthropathy, and diabetes‐associated lower extremity amputation.Methods: We collected data reporting 5‐year mortality from studies published following 2007 and calculated a pooled mean. We evaluated data from DFU, Charcot arthropathy and lower extremity amputation. We dichotomized high and low amputation as proximal and distal to the ankle, respectively. This was compared with cancer mortality as reported by the American Cancer Society and the National Cancer Institute.Results: Five year mortality for Charcot, DFU, minor and major amputations were 29.0, 30.5, 46.2 and 56.6%, respectively. This is compared to 9.0% for breast cancer and 80.0% for lung cancer. 5 year pooled mortality for all reported cancer was 31.0%.Direct costs of care for diabetes in general was $237 billion in 2017. This is compared to $80 billion for cancer in 2015. As up to one‐third of the direct costs of care for diabetes may be attributed to the lower extremity, these are also readily comparable.Conclusion: Diabetic lower extremity complications remain enormously burdensome. Most notably, DFU and LEA appear to be more than just a marker of poor health. They are independent risk factors associated with premature death. While advances continue to improve outcomes of care for people with DFU and amputation, efforts should be directed at primary prevention as well as those for patients in diabetic foot ulcer remission to maximize ulcer‐free, hospital‐free and activity‐rich days.

1 May 1998 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
David ArmstrongDavid Armstrong
David Armstrong
LLLawrence A Lavery
Lawrence A Lavery
LHLawrence B Harkless
Lawrence B Harkless
OBJECTIVE To validate a wound classification instrument that includes assessment of depth, infection, and ischemia based on the eventual outcome of the wound. RESEARCH DESIGN AND METHODS We evaluated the medical records of 360 diabetic patients presenting for care of foot wounds at a multidisciplinary tertiary care foot clinic. As per protocol, all patients had a standardized evaluation to assess wound depth, sensory neuropathy, vascular insufficiency, and infection. Patients were assessed at 6 months after their initial evaluation to see whether an amputation had been performed. RESULTS There was a significant overall trend toward increased prevalence of amputations as wounds increased in both depth (χ2trend = 143.1, P < 0.001) and stage (χ2trend = 91.0, P < 0.001). This was true for every subcategory as well with the exception of noninfected, nonischemic ulcers. There were no amputations performed within this stage during the follow-up period. Patients were more than 11 times more likely to receive a midfoot or higher level amputation if their wound probed to bone (18.3 vs. 2.0%, P < 0.001, χ2 = 31.5, odds ratio (OR) = 11.1, CI = 4.0–30.3). Patients with infection and ischemia were nearly 90 times more likely to receive a midfoot or higher amputation compared with patients in less advanced wound stages (76.5 vs. 3.5%, P < 0.001, χ2 = 133.5, OR = 89.6, CI = 25–316). CONCLUSIONS Outcomes deteriorated with increasing grade and stage of wounds when measured using the University of Texas Wound Classification System.

1 November 2005 in The Lancet
Verified
Journal Article
Closed access
David ArmstrongDavid Armstrong
David Armstrong
LLLawrence A Lavery
Lawrence A Lavery
DCDiabetic Foot Study Consortium
Diabetic Foot Study Consortium

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
LDLiling Deng
Liling Deng
CDChenzhen Du
Chenzhen Du
PSPeiyang Song
Peiyang Song
TCTianyi Chen
Tianyi Chen
SRShunli Rui
Shunli Rui
WDWuquan Deng
Wuquan Deng
Foot ulcers are one of the most common and severe complication of diabetes mellitus with significant resultant morbidity and mortality. Multiple factors impair wound healing include skin injury, diabetic neuropathy, ischemia, infection, inadequate glycemic control, poor nutritional status, and severe morbidity. It is currently believed that oxidative stress plays a vital role in diabetic wound healing. An imbalance of free radicals and antioxidants in the body results in overproduction of reactive oxygen species which lead to cell, tissue damage, and delayed wound healing. Therefore, decreasing ROS levels through antioxidative systems may reduce oxidative stress‐induced damage to improve healing. In this context, we provide an update on the role of oxidative stress and antioxidants in diabetic wound healing through following four perspectives. We then discuss several therapeutic strategies especially dietary bioactive compounds by targeting oxidative stress to improve wounds healing.

1 June 2001 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
David ArmstrongDavid Armstrong
David Armstrong
HNHienvu C. Nguyen
Hienvu C. Nguyen
LLLawrence A. Lavery
Lawrence A. Lavery
CSCarine H.M. van Schie
Carine H.M. van Schie
ABAndrew J.M. Boulton
Andrew J.M. Boulton
LHLawrence B. Harkless
Lawrence B. Harkless
OBJECTIVE—To compare the effectiveness of total-contact casts (TCCs), removable cast walkers (RCWs), and half-shoes to heal neuropathic foot ulcerations in individuals with diabetes. RESEARCH DESIGN AND METHODS—In this prospective clinical trial, 63 patients with superficial noninfected, nonischemic diabetic plantar foot ulcers were randomized to one of three off-loading modalities: TCC, half-shoe, or RCW. Outcomes were assessed at wound healing or at 12 weeks, whichever came first. Primary outcome measures included proportion of complete wound healing at 12 weeks and activity (defined as steps per day). RESULTS—The proportions of healing for patients treated with TCC, RCW, and half-shoe were 89.5, 65.0, and 58.3%, respectively. A significantly higher proportion of patients were healed by 12 weeks in the TCC group when compared with the two other modalities (89.5 vs. 61.4%, P = 0.026, odds ratio 5.4, 95% CI 1.1–26.1). There was also a significant difference in survival distribution (time to healing) between patients treated with a TCC and both an RCW (P = 0.033) and half-shoe (P = 0.012). Patients were significantly less active in the TCC (600.1 ± 320.0 daily steps) compared with the half-shoe (1,461.8 ± 1,452.3 daily steps, P = 0.04). There was no significant difference in the average number of steps between the TCC and the RCW (767.6 ± 563.3 daily steps, P = 0.67) or the RCW and the half-shoe (P = 0.15). CONCLUSIONS—The TCC seems to heal a higher proportion of wounds in a shorter amount of time than two other widely used off-loading modalities, the RCW and the half-shoe.

1 December 2007 in The American Journal of Medicine
Verified
Journal Article
Closed access
David ArmstrongDavid Armstrong
David Armstrong
KHKatherine Holtz-Neiderer
Katherine Holtz-Neiderer
CWChristopher Wendel
Christopher Wendel
MMM. Jane Mohler
M. Jane Mohler
HKHeather R. Kimbriel
Heather R. Kimbriel
LLLawrence A. Lavery
Lawrence A. Lavery